九福来

Jufeel was approved to go public, will soon go for the road show in US.

Jufeel was approved to go public, will soon go for the road show in US.

  On March 29, 2019, Eastern American Time (March 29, 2019 Beijing Time), Jufeel International Group (Code: CNJG) was approved and came in to force by SEC following several rounds of reviews. As the first Chinese Aloe Vera biological comprehensive health company, Jufeel International Group, the effectiveness of S-1 filing is a historic moment, which means Jufeel shares will go to public for the first time. It demonstrates markedly the strength of the group and steady development perspective, displays the incredible value growth room.

  According to official Website of NASDAQ, Jufeel International Group (Code: CNJG) is categorized in the biological technology industry, its main business direction is medicinal chemicals and plant products. The major business income in China is from the business module of aloe biological industry chain.

  As the information shows, Jufeel is a comprehensive hi-tech enterprise, who dedicates in aloe vera organic planting, raw materials processing, biological extraction, deep research and development etc at its core. It occupies the high-end raw materials market in China’s aloe vera industry, as well as a reputed brand with more influence in China. The aloe vera products have been certificated organic planting and processing certificate in China, EU, US (NOP), Japan (JAS); Europe (ECO), KOSHER, PONY, Swiss (SGS), and certificate by International Aloe Science Council. The products are popular in dozens of countries, such as US, Italy, Germany, Spain, New Zealand, Australia, Japan,South Korea, Malaysia etc; Jufeel partners with a number of world-renowned companies as the long-term supplier of raw materials.

  Jufeel has accomplished a complete aloe vera industry chain, the planting base in the size of 1850 mu; raw materials processing and extraction center in Haikou; manufacturing center, marketing center in Zhengzhou and PMAS manufacturing base in Kaifeng; Jufeel Changzhou University research and development center and joint research center in Taiwan. Jufeel is the holder of multiple technology patents in China, USA, and Hong Kong etc, part of the patents have been reviewed by PCT (Patent Cooperation Treaty) and leading in the world.

  As the information shows, in recent years, Jufeel has cooperated closely with several reputed institutions to conduct joint research and clinical trials, naming Nanjing University Chinese Medicine, Changzhou University College of Pharmaceutical and Life Science, Chung Shan Medical University, the General Hospital of the PLA (301 Hospital), continuous breakthroughs have been made and repeated wins of international awards have been reaped. Among them, the prominent awards, such as World Outstanding AIDS Prevention Invention Award conferred by WAOUN, Gold Award of Medical Health in 46th Geneva Inventions Salon, Certificate of Recognition at the 20th International Conference on STD-AIDS and infectious Diseases in Bangkok by the organizing Committee, whom are from University of Oxford, University of Strasbourg and University of California.

  In recent, Jufeel established collaboration with another well-renewed institution, Zhejiang University. The cooperation agreement on development of new anti-HIV medicines from natural Polysaccharide compound PMAS has been signed by two parties, to further conduct clinical trial with Jufeel’s patented “PMAS”, aiming at the development of safe and non-toxic side effect anti-HIV medicines. Prior to this cooperation, Jufeel has been keeping frequent cooperation and communication with Tanzania National Institute of Medical Research, and sponsored them valuable of related biological products to conduct clinical trial on HIV/AIDS, from which fruitful results have been achieved.

  It is reported that, since end of 2016, Jufeel has commenced the planning of overseas listing, in particular the IPO; the company has endured great pressure and setbacks during the process. Eventually this time, Jufeel has received the approval of S-1 document from SEC, marking the ice-breaking journey of overseas listing for Chinese aloe vera biological company. Furthermore, it is the reward of long-time unwavering pursuit and of strategic significance of Jufeel’s future development. The public information from SEC displays that, the net profit of Jufeel has exceeded ten million US dollars in 2017 and maintain a good progressive momentum in 2018. The promising prospect of development in 2019 and the future will be demonstrated in the prospectus. There is no doubt that Jufeel has a remarkable growing potential; and the reliable source confirmed that Jufeel would kick off the road show in US for further capital raisings, Jufeel would soon commence the preparation of prospectus, submit and choose to list between NASDAQ and NYSE.

Back to list